Eventide Healthcare & Life Sciences has been a strong performer in its biotech niche, but a tough 2020 highlights the risks involved. The I shares maintain their Morningstar Analyst Rating of Bronze, while the A, C, and N shares are rated Neutral.
Will ETIHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable ETIHX’s performance objective and investment process is for both security selection and portfolio construction.
The People Pillar is our evaluation of the ETIHX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
The Parent Pillar is our rating of ETIHX’s parent organization’s priorities and whether they’re in line with investors’ interests.